×

Important Information

This section of the website (the “Microsite”) of Mereo BioPharma Group plc (the “Company”) has been prepared solely for your information and for the purpose of providing background information on the Company, its business, the upcoming general meeting of the Company’s shareholders, and the industry in which the Company operates or any particular aspect thereof. For further information, please see the shareholder circular published by the Company in connection with the General Meeting which is available at www.mereobiopharma.com/GeneralMeeting2022 or at sec.gov.

The information contained in the Microsite has not been independently verified and no representation or warranty, express or implied, is made or given by or on behalf of the Company or any of its subsidiaries, or any of any such person’s directors, officers, employees, agents, affiliates or advisers, as to, and no reliance should be placed on, the accuracy, completeness or fairness of the information or opinions contained in the Microsite and no responsibility or liability is assumed by any such persons for any such information or opinions or for any errors or omissions. All information presented or contained in the Microsite is subject to verification, correction, completion and change without notice. In making available the Microsite, none of the Company or any of its subsidiaries, or any of any such person’s directors, officers, employees, agents, affiliates or advisers, undertakes any obligation to amend, correct or update the information contained in the Microsite or to provide the recipient with access to any additional information that may arise in connection with it. Accordingly, undue reliance should not be placed on any of the data contained in the Microsite.

Forward-Looking Statements

The Microsite and the information in it contain “forward-looking statements.” All statements other than statements of historical fact are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements relate to future events, including, but not limited to, statements regarding future clinical development, efficacy, safety and therapeutic potential of clinical product candidates, including expectations as to reporting of data, conduct and timing and potential future clinical activity and milestones and expectations regarding the initiation, design and reporting of data from clinical trials. Forward-looking statements are often identified by the words “believe,” “expect,” “anticipate,” “plan,” “intend,” “foresee,” “should,” “would,” “could,” “may,” “estimate,” “outlook” and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company’s current expectations, beliefs and assumptions concerning future developments and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company’s business, including those described in the “Risk Factors” section of its latest Annual Report on Form 20-F, reports on Form 6-K and other documents furnished or filed from time to time by the Company with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law. The Microsite and the information in it also contain estimates, projections and other information concerning the Company’s business and the markets for the Company’s product candidates, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research, or similar methodologies is inherently subject to uncertainties and actual events, or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, the Company obtained this industry, business, market and other data from reports, research surveys, clinical trials studies and similar data prepared by market research firms and other third parties, from industry, medical and general publications, and from government data and similar sources.

OK

Shareholder Meetings

AGM 2021

RESOLUTION VOTES FOR  %OF SHARES VOTED VOTES AGAINST  % OF SHARES VOTED VOTES WITHHELD 
1. Adoption of UK Annual Accounts 256,674,400 99.95 132,785 0.05 73,310
2. Re-appointment of auditor 256,698,040 99.96 107,865 0.04 74,410
3. Remuneration of auditor 256,605,855 99.92 201,170 0.08 73,290
4. Approval of UK Directors' Remuneration Report 211,349,035 82.34 45,322,225 17.66 209,055
5. Approval of UK Directors' Remuneration Policy 210,914,645 82.31  45,338,865 17.69 626,805
6. Re-appointment of Dr Jeremy Bender 213,213,235 83.07 43,464,070 16.93 203,010
7. Re-appointment of Dr Brian Schwartz 213,143,345 83.04 43,537,680 16.96 199,290
8,. Re-appointment of Dr Peter Fellner 256,421,285 99.89 271,925 0.11 187,105
9. Re-appointment of Dr Denise Scots-Knight 256,394,130 99.89 287,365 0.11 198,820
10. Re-appointment of Peter Bains 256,394,930 99.89 281,110 0.11 204,275
11. Re-appointment of Dr Anders Ekblom 213,195,915 83.06 43,486,640 16.94 197,760
12. Re-appointment of Kunal Kashyap 213,123,600 83.04 43,535,665 16.96 221,050

A “Withheld” vote is not a vote in law and is not counted in the calculation of the votes “For” or “Against” a resolution